Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application

Cutis. 2011 Aug;88(2):67-72.


Azelaic acid (AzA) gel 15% is approved by the US Food and Drug Administration (FDA) for the treatment of papulopustular rosacea (PPR). Its efficacy and safety as monotherapy have been demonstrated. Release of active drug from the gel formulation is superior to the cream. The combination of AzA gel 15% with oral doxycycline appears to expedite and augment response, especially in cases of PPR of greater severity, and AzA gel 15% maintains control of PPR over 6 months as compared to vehicle. Adjunctive skin care is recommended to augment the therapeutic outcome of PPR and reduce the potential for irritation that can occur with topical therapy.

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Dermatologic Agents / administration & dosage
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Dicarboxylic Acids / administration & dosage
  • Dicarboxylic Acids / adverse effects
  • Dicarboxylic Acids / therapeutic use*
  • Doxycycline / administration & dosage
  • Doxycycline / adverse effects
  • Doxycycline / therapeutic use
  • Drug Therapy, Combination
  • Gels
  • Humans
  • Rosacea / drug therapy*
  • Rosacea / pathology
  • Severity of Illness Index


  • Anti-Bacterial Agents
  • Dermatologic Agents
  • Dicarboxylic Acids
  • Gels
  • azelaic acid
  • Doxycycline